Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATOS Atossa Genetics	$0.89 -2.9%	$0.86	$0.55 ▼ $1.66	$114.45M	0.9	750,367 shs	148,985 shs
CRDL Cardiol Therapeutics	$1.29 -0.4%	$1.29	$0.77 ▼ $2.63	$106.21M	1.04	306,541 shs	26,519 shs
IGXT IntelGenx Technologies	$0.17	$0.17	$0.09 ▼ $0.22	$29.17M	2.47	N/A	N/A
ONCY Oncolytics Biotech	$1.19 +4.9%	$0.63	$0.33 ▼ $1.53	$112.39M	1.07	722,805 shs	289,375 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATOS Atossa Genetics	-2.33%	+7.98%	+10.15%	+51.21%	-34.66%
CRDL Cardiol Therapeutics	-3.01%	-7.86%	-11.64%	+27.72%	-39.44%
IGXT IntelGenx Technologies	0.00%	0.00%	0.00%	0.00%	0.00%
ONCY Oncolytics Biotech	-5.83%	-9.60%	+85.86%	+98.94%	+4.63%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATOS Atossa Genetics	3.1476 of 5 stars	3.7	4.0	0.0	0.0	3.8	1.7	0.0
CRDL Cardiol Therapeutics	2.4275 of 5 stars	3.7	3.0	0.0	0.0	2.7	0.0	0.6
IGXT IntelGenx Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	1.4862 of 5 stars	3.4	3.0	0.0	0.0	1.5	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATOS Atossa Genetics	3.33	Buy	$6.17	594.44% Upside
CRDL Cardiol Therapeutics	3.33	Buy	$8.00	522.57% Upside
IGXT IntelGenx Technologies	0.00	N/A	N/A	N/A
ONCY Oncolytics Biotech	2.75	Moderate Buy	$4.33	265.68% Upside

Current Analyst Ratings Breakdown

Latest IGXT, CRDL, ONCY, and ATOS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/6/2025	ATOS Atossa Genetics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.25 ➝ $7.50
6/5/2025	ATOS Atossa Genetics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$4.00
6/2/2025	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00
5/21/2025	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
5/16/2025	ONCY Oncolytics Biotech	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
4/21/2025	ATOS Atossa Genetics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $7.25
4/16/2025	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	$0.57 per share	N/A
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	$0.22 per share	N/A
IGXT IntelGenx Technologies	$1.04M	28.05	N/A	N/A	($0.07) per share	-2.39
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	$0.05 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATOS Atossa Genetics	-$25.50M	-$0.21	N/A	N/A	N/A	N/A	-33.90%	-31.53%	8/11/2025 (Estimated)
CRDL Cardiol Therapeutics	-$26.77M	-$0.34	N/A	N/A	N/A	N/A	-209.63%	-141.09%	8/11/2025 (Estimated)
IGXT IntelGenx Technologies	-$9.93M	-$0.06	N/A	∞	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	-$23.14M	-$0.29	N/A	N/A	N/A	N/A	-313.77%	-130.19%	7/30/2025 (Estimated)

Latest IGXT, CRDL, ONCY, and ATOS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	ATOS Atossa Genetics	-$0.06	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	CRDL Cardiol Therapeutics	-$0.11	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	ONCY Oncolytics Biotech	-$0.10	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	ONCY Oncolytics Biotech	-$0.09	-$0.06	+$0.03	-$0.06	N/A	N/A
5/13/2025	Q1 2025	ATOS Atossa Genetics	-$0.06	-$0.05	+$0.01	-$0.05	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	N/A
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	N/A
IGXT IntelGenx Technologies	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATOS Atossa Genetics	N/A	12.67	12.67
CRDL Cardiol Therapeutics	0.01	3.26	3.26
IGXT IntelGenx Technologies	N/A	N/A	N/A
ONCY Oncolytics Biotech	N/A	3.20	3.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATOS Atossa Genetics	12.74%
CRDL Cardiol Therapeutics	12.49%
IGXT IntelGenx Technologies	N/A
ONCY Oncolytics Biotech	6.82%

Insider Ownership

Company	Insider Ownership
ATOS Atossa Genetics	8.70%
CRDL Cardiol Therapeutics	5.25%
IGXT IntelGenx Technologies	42.05%
ONCY Oncolytics Biotech	0.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATOS Atossa Genetics	8	129.17 million	117.93 million	Optionable
CRDL Cardiol Therapeutics	20	82.65 million	78.31 million	Not Optionable
IGXT IntelGenx Technologies	38	174.66 million	101.21 million	Not Optionable
ONCY Oncolytics Biotech	30	94.28 million	94.19 million	Not Optionable

IGXT, CRDL, ONCY, and ATOS Headlines

Recent News About These Companies

Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types

2 hours ago | prnewswire.com

Oncolytics Biotech Inc. (ONCY) - Yahoo Finance Canada

July 11, 2025 | ca.finance.yahoo.com

USA News Group: Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up

July 10, 2025 | finanznachrichten.de

Oncolytics Biotech to Host Webinar on Pelareorep’s Potential in Cancer Treatment

July 10, 2025 | tipranks.com

Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers

July 10, 2025 | prnewswire.com

Oncolytics Biotech Highlights Promising Pelareorep Data in Cancer Treatment

July 10, 2025 | theglobeandmail.com

Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies - The Globe and Mail

July 9, 2025 | theglobeandmail.com

Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies

July 8, 2025 | prnewswire.com

Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Average Recommendation of "Moderate Buy" by Analysts

July 5, 2025 | marketbeat.com

Oncolytics Biotech Inc. (NASDAQ:ONCY) Receives Average Rating of "Moderate Buy" from Brokerages

July 5, 2025 | marketbeat.com

Oncolytics Biotech (NASDAQ:ONCY) Trading Down 3% - Should You Sell?

July 1, 2025 | marketbeat.com

Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy

June 30, 2025 | prnewswire.com

With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology

June 20, 2025 | newswire.ca

Private-Sector Oncology May Be the Market’s Best-Understood Secret

June 20, 2025 | baystreet.ca

USA News Group: With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology

June 20, 2025 | finanznachrichten.de

USA News Group: Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going

June 18, 2025 | finanznachrichten.de

After Major Oncology Conference, All Eyes Turn to Industry Innovation

June 12, 2025 | prnewswire.co.ukP

Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs

June 11, 2025 | prnewswire.com

Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities

May 23, 2025 | prnewswire.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Immunome (IMNM), Oncolytics Biotech (ONCY) and Hookipa Pharma (HOOK)

May 18, 2025 | theglobeandmail.com

Jones Trading Downgrades Oncolytics Biotech (ONCY)

May 17, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IGXT, CRDL, ONCY, and ATOS Company Descriptions

Atossa Genetics NASDAQ:ATOS

$0.89 -0.03 (-2.93%)

As of 10:18 AM Eastern

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Cardiol Therapeutics NASDAQ:CRDL

$1.28 -0.01 (-0.39%)

As of 10:16 AM Eastern

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

IntelGenx Technologies OTCMKTS:IGXT

$0.17 0.00 (0.00%)

As of 05/27/2025

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

Oncolytics Biotech NASDAQ:ONCY

$1.18 +0.06 (+4.87%)

As of 10:17 AM Eastern

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time